AI-driven precision biotechnology company Gandeeva Therapeutics has entered a research collaboration with biotechnology company Moderna to explore how Gandeeva’s technology platform can be utilized in one of Moderna’s programs.

Under the terms of the agreement, both companies will work together to study and validate the application of Gandeeva's proprietary cryogenic electron microscopy (cryo-EM) platform approach for a Moderna target. Further, Gandeeva will receive research payments from Moderna. 

Canadian AI precision company Gandeeva Therapeutics develops precision medicines by leveraging AI/ML, structural biology, biochemistry, and imaging technologies. It follows the cryogenic electron microscopy (cryo-EM) approach that captures detailed images of proteins to determine their structures to the level as small as two angstroms (one-tenth of a nanometer) and zoom in on specific areas of a protein, thereby providing insights to accelerate the drug discovery process.